Abstract
INVITRO EVALUATION OF GEMCITABINE AND ITS DERIVATIVE (GEMCITABINE-ERLOTINIB) FOR THE TREATMENT OF PANCREATIC CANCER
Dr. Syed Ahmed Hussain*, Shaik Nazma Sultana, Sara Umm E. Hani, Farahanaaz Begum and Juveria Gaffar
ABSTRACT
This research paper examines the cellular impact of Gemcitabine-Erlotinib combination therapy on viability, tubulogenesis, and protein expression levels using MTT assay, Tubulogenesis assay, Indirect Immunofluorescence assay, and Western Blot analysis. The study encompasses four treatment groups: Group 1 (normal), Group 2 (Control cell line), Group 3 (Standard GEMCITABINE), and Group 4 (Gemcitabine-Erlotinib). The results suggest that Gemcitabine-Erlotinib has a significant effect on cell viability and tubulogenesis, while also affecting protein expression levels. These findings emphasize the potential impact of this combination therapy on cellular processes and warrant further investigation.
[Full Text Article] [Download Certificate]WJPLS CITATION 
All | Since 2020 | |
Citation | 590 | 424 |
h-index | 12 | 10 |
i10-index | 17 | 14 |
INDEXING
NEWS & UPDATION
BEST ARTICLE AWARDS
World Journal of Pharmaceutical and life sciences is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.
Best Article of current issue
Download Article : Click here